Gyala Therapeutics — Series A

CDTI Innovación announced, via its Innvierte programme, that it is entering the capital of Gyala Therapeutics alongside NARA Health Capital and founding investor Invivo Ventures; CDTI's committed ticket is €540,000 and the total round size was not disclosed. Gyala is a Hospital Clínic-IDIBAPS spin-off developing GYA01, a first-in-class CD84-targeting CAR-T therapy, and the money funds a Phase I trial in relapsed/refractory acute myeloid leukaemia.